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j ourna l homepage: www.eb iomed ic ine.comCommentaryThe detection of donor-derived cell-free DNA may serve as a biomarker
for the early detection of chronic lung allograft dysfunctionSandhya Bansal, Timothy Fleming, Thalachallour Mohanakumar ⁎
Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ 85013, United StatesA sobering statistic is that 50% of all lung transplants fail by year 5 utility of ddcfDNA as an early, noninvasive rejection marker [4,7].
due to chronic rejection, also called chronic lung allograft dysfunction
(CLAD). Among the subtypes of CLAD, bronchiolitis obliterans syn-
drome (BOS) is the most common and is the principal factor limiting
long-term transplant survival. Research is ongoing for predicting
which patients will be at risk for developing BOS and undergo chronic
lung transplant rejection. A new study by Agbor-Enoh et al. in
EBioMedicine [1] addresses a biomarker assay, donor derived cell-free
DNA (ddcfDNA) that may provide an early identiﬁcation of patients at
risk for developing BOS. Currently, there is no reliable predictor for pa-
tients experiencing BOS and the study by Agbor-Enoh presents a poten-
tial predictor for the early detection of BOS. A biomarker that can help
predict CLAD has key applications in the clinic as well as to basic scien-
tists who are searching for the immunologic features that initiate and
progress to chronic rejection.
Cell-free DNA (cfDNA) is fragmented DNA in the bloodstream that
originates from both cell injury and cell death. The authors [1] have
taken advantage of detecting this circulating donor DNA as a metric in
determining damage to the transplanted lung.When graft injury occurs
due to immunologic rejection, donor-derived cell-free-DNA is detect-
able in the blood of these patients.
cfDNA is not only useful as a biomarker in transplant rejection but
also can serve as a potential biomarker in different kinds of disease in-
cluding stroke, trauma, myocardial infarction, autoimmune disorders,
and pregnancy-associated complications. The pattern developing is
that there are generally higher concentrations of cfDNA in disease vs
healthy individuals. Presence of genetic anomalies including mutations
(K-ras, TP53, EGFR etc.), genetic rearrangements, copy number
variation, chromosomal rearrangements, methylation changes (APC,
ALX4) can be related to cfDNA's in circulation in different kinds of can-
cers [2–4].
Donor derived cell-free DNA (ddcfDNA) is the terminology for trans-
plant donor DNA and quantiﬁcation techniques have been employed as
an assay for analyzing the presence of donor DNA in plasma. The detec-
tion and understanding of ddcfDNA kinetics following transplantation
may provide clues for transplant success [5,6]. Alterations in the levels
of ddcfDNA during acute/chronic rejection are detectable prior to clini-
cal diagnosis or pathological features of graft rejection, suggesting theDOI of original article: https://doi.org/10.1016/j.ebiom.2018.12.029.
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2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article underAlthough the precise mechanism of release of cfDNA is unknown, the
detection of cfDNA in blood, plasma and urine can be a predictive bio-
marker [8].
Lung transplantation is the treatment option for organ failure. The
current assay described by Agbor-Enoh et al. [1] for ddcfDNA in lung
transplant patients will be a powerful tool in identifying patients “at
risk” for developing rejection and will be critical in developing treat-
ment strategies that will impact lung transplant outcome. While this
assay provides an early detection for BOS, there currently are no thera-
peutic modalities to prevent or cure chronic lung rejection once it is
established. However, this method for early detection of BOS does
allow researchers to evaluate changes in immune modulatory mole-
cules and T regulatory cells that may prove to be important in develop-
ing novel treatment strategies.
Different research groups have investigated the role of ddcfDNA in a
variety of organ transplants including kidney, heart, liver and lung, and
have shown that ddcfDNA can be reliably detected and there is a posi-
tive correlation to organ rejection. Synder et al. addressed the chal-
lenges involved in monitoring the rejection of solid organ transplants
(heart transplant) by host immune system [9] and ddcfDNA was
found to be signiﬁcantly elevated in the circulating blood of heart trans-
plant recipients which has been correlated to acute cellular rejection. A
research article published byDeVlaminck et al. presented the outcomes
and correlation of ddcfDNA post heart transplant [7]. Elevation in
the levels of circulatory ddcfDNA occurred prior to the development
of rejection on endomyocardial biopsy. This study employed shotgun
sequencing of SNP basedmarkers to discriminate between donor recip-
ient pairs and validated their approach to sexmatched andmismatched
donor-recipient pairs. Zou et al. [10] employed a different platform in
which lung transplant donor-recipients genomics-based approach
using mismatched HLA allele was employed. They also noted increased
levels of donor ddcfDNA in the circulation prior to clinical diagnosis of
rejection. However, they pointed out that viral infections can also result
in increased levels of circulating ddcfDNA and therefore differential
diagnosis is important.
The developing impact of ddcfDNA as a biomarker in monitoring
transplant rejection is evident by a recent FDA-approved assay for kid-
ney transplant patients [11]. The assay measures donor-derived
cfDNA, as a direct indicator of kidney injury and predictor of rejection.
The current article (eBIO) makes a compelling case that ddcfDNAthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
14 S. Bansal et al. / EBioMedicine 40 (2019) 13–14measured early after lung transplantation can be a reliable assessment
for diagnosis of BOS and chronic lung transplant rejection.
The impact of the current study by Agbor-Enoh et al. [1] established
a ready-to-use assay system, the detection of ddcfDNA, that appears to
predict chronic graft failure in lung transplant recipients. Early detection
of chronic graft rejection will provide a window of opportunity to ad-
dress immunologicmechanisms that result in BOS and transplant rejec-
tion. The Agbor-Enoh et al. study is the ﬁrst to demonstrate that
elevated ddcfDNA in ﬁrst 3 months after transplant can predict long
term outcomes, including progression to chronic rejection. The detec-
tion of elevated ddcfDNA in ﬁrst 3 months after transplant provides a
tool to assess efﬁcacy of early treatment with currently available
drugs, as well as new targeted therapies as they as developed.
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